Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder

Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the relationship of its daily steady‐state exposure (C(av,ss)) to the probability of most frequent t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Autores principales: Lalovic, Bojan, Majid, Oneeb, Aluri, Jagadeesh, Landry, Ishani, Moline, Margaret, Hussein, Ziad
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Pharmacometrics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689791/
https://ncbi.nlm.nih.gov/pubmed/32666570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1683
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares